Clinical Study of Sijihong and Other Chinese Medicinal Materials in the Treatment of Cystitis after Bone Marrow Transplantation in Patients with Acute Myeloid Leukemia
Jun Chen, Shujie Mao, Nini Liu, Dousong Lin, Longfei Zhao, Zhihong Lin, Mingming Hu, Siyi Wei, Xianzhong Zeng, Huiying QiuBackground:
Acute myeloid leukemia (AML) is a malignant hematologic tumor for which bone marrow transplantation (BMT) is an effective treatment, but hemorrhagic cystitis (HC) is a common and burdensome post-transplant complication. Safe and effective therapies for HC after BMT are needed.
Aims and Objectives:
To evaluate the clinical efficacy of the Ningmitai capsule in treating HC after BMT in patients with AML and to explore its effects on bladder function and inflammatory markers.
Materials and Methods:
Sixty AML patients who developed HC after BMT were randomly assigned to an observation group (n = 30) and a control group (n = 30). Both groups received conventional hydration and alkaline diuresis; the control group additionally received moxifloxacin hydrochloride tablets, while the observation group received Ningmitai capsules on the basis of conventional treatment for 2 weeks. Clinical efficacy, urodynamic indexes (maximum urinary flow rate, MFR; residual volume of urine, RVU), and serum levels of interleukin (IL)-6, IL-1β, IL-8, and tumor necrosis factor-α (TNF-α) were assessed before and after treatment.
Results:
The total effective rate was significantly higher in the observation group than in the control group. After treatment, MFR increased and RVU decreased significantly in the observation group compared with both baseline and the control group. Serum levels of IL-6, IL-1β, IL-8, and TNF-α decreased in both groups, with significantly lower levels in the observation group than in the control group (all P<0.05 P<0.05).
Conclusion:
The Ningmitai capsule can effectively improve clinical symptoms and bladder function and reduce systemic inflammation in AML patients with HC after BMT. These benefits may be related to the anti-inflammatory and diuretic effects of its main active components, including gallic acid and quercetin. Ningmitai capsule is therefore a promising treatment option for HC after BMT.